Gl701
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
127 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 2 | 3 | 7 | 2 | 5 | 16 |
| Atrophic vaginitis | D059268 | EFO_1001271 | — | 1 | 1 | 8 | 2 | — | 12 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | 3 | 2 | 2 | 10 |
| Dyspareunia | D004414 | — | N94.1 | — | — | 2 | 2 | — | 4 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 2 | — | 1 | — | 3 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 1 | 1 | 2 |
| Fatigue | D005221 | — | R53.83 | — | 1 | — | 1 | — | 2 |
| Contraception behavior | D003268 | — | — | — | — | — | 1 | — | 1 |
| Blood coagulation | D001777 | GO_0007596 | — | — | — | — | 1 | — | 1 |
| Frailty | D000073496 | — | R53.1 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 4 | 6 | — | — | 8 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 3 | 4 | 2 | — | — | 5 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | 3 | — | 1 | 4 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | 1 | — | 3 | 4 |
| Communicable diseases | D003141 | — | — | — | 2 | 2 | — | 1 | 4 |
| Rare diseases | D035583 | — | — | — | 2 | 3 | — | — | 4 |
| Female infertility | D007247 | EFO_0008560 | N97 | 1 | 1 | 1 | — | 1 | 3 |
| Psychological sexual dysfunctions | D020018 | — | F52.0 | — | — | 2 | — | 1 | 3 |
| Metabolic bone diseases | D001851 | — | — | — | — | 2 | — | 1 | 3 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | 2 | 2 | — | — | 3 |
Show 32 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male breast neoplasms | D018567 | — | — | 1 | 1 | — | — | — | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | — | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | — | — | 1 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | 1 | — | — | — | 1 |
| Libido | D007989 | — | R68.82 | — | 1 | — | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 1 | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | — | — | — | 1 | 3 |
| Menstruation disturbances | D008599 | — | N91.5 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Metabolic side effects of drugs and substances | D065606 | — | — | 1 | — | — | — | — | 1 |
| Synovial sarcoma | D013584 | — | — | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Hypoglycemia | D007003 | — | E16.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 5 | 5 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 5 | 5 |
| Syndrome | D013577 | — | — | — | — | — | — | 4 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 2 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 2 | 2 |
| Sclerosis | D012598 | — | — | — | — | — | — | 2 | 2 |
| Hyperandrogenism | D017588 | — | — | — | — | — | — | 2 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
Show 50 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use